ENVB חוב כולל להון Enveric

Enveric Biosciences (ENVB) is developing the Psybrary AI system, creating a proprietary registry of psychedelic compounds for mental health therapy within the B2B sector. The daily price action for the debt-to-equity ratio is recorded at 0.00. The financial model relies on future sales of treatments for depression and anxiety in cancer patients, while revenue remains in the early stages through the development of new drugs.

Enveric Biosciences (ENVB) is currently focusing on the intensive development of synthetic psilocybin derivatives for the treatment of anxiety disorders. By analyzing the company's financial leverage history, an investor evaluates the debt-to-equity ratio, which determines the extent of the R&D pipeline's dependence on external creditors and assesses the stability of the financing structure during the peak of research activity.